CAMBRIDGE, Mass.--(BUSINESS WIRE)--TransMolecular, Inc., a biotechnology company focused on targeted therapies for cancer, today announced the appointment of Nicholas C. Nicolaides, Ph.D., as Non-Executive Chairman of the Company’s Board of Directors. Dr. Nicolaides currently serves as President and CEO of Morphotek, Inc., a subsidiary of Eisai Co., Ltd.
